Grotex

Grotex is engaged in the production of pharmaceutical substances.

History

2025: ₽400 Million Robotic Syringe Production Launch for ₽400 Million

Pharmaceutical company Solopharm has launched a high-tech site to produce pre-filled syringes and vials of hyaluronic acid. The company announced this at the end of October 2025.

Investments in the project amounted to ₽400 million. The company has mastered its own technology for the production of crosslinked hyaluronic acid. The launch was the first section in Russia with two automated lines for this type of product.

𝓲

Фото: Freepik

Crosslinked hyaluronic acid is the result of a complex technological process. Crosslinking allows you to create stable gel preparations with prolonged action. High elastic properties ensure effective use in injectable cosmetology.

The drugs are also used in rheumatology and traumatology. The technology makes it possible to control the viscosity and elasticity of the gel. The stability of the compounds provides a long-lasting therapeutic effect.

The company's CEO, Mamuka Mikhelashvili, said the company had made the difficult journey of more than two years to develop hyaluronic acid crosslinking technology. It took a long time to develop analytical methods.

The CEO of the company Mamuka Mikhelashvili noted the need to determine the quantitative content of crosslinked hyaluronic acid and crosslinker BDDE. Microbiological methods control bacterial endotoxins and sterility. This makes it possible to produce high-quality and safe drugs.

General Director of the company Mamuka Mikhelashvili stressed that thanks to a well-coordinated team of highly qualified specialists, the company is mastering new and complex technologies. The goal is to offer the medical community and patients Russian products of the highest quality that meet all GMP standards.^[1]

2024: 8th place in drug sales in Russia - 116.9 million packages

At the end of 2024, Groteks took the 8th place in sales of drugs in Russia with sales of 116.9 million packages. This is stated in a study by the DSM Group, the results of which TAdviser got acquainted with in early December 2025. Read more here

2023

Change of CEO - Pavel Semyanov appointed him

On June 23, 2023, Pavel Semyanov was appointed the new general director of the St. Petersburg pharmaceutical company Solopharm (LLC Grotex""). He replaced Oleg Zherebtsov, who took over as chairman of the board of directors of Groteks LLC and head of Solopharm Group of Companies. here More.

Start of construction of the pharmaceutical plant for 9.5 billion rubles

In June 2023, the foundation of a pharmaceutical plant for the production of hormonal drugs was laid in St. Petersburg. The company was named Hormones Plant. The project is being implemented by Solopharm. Read more here.

Notes